NYSE:EBS Emergent Biosolutions (EBS) Stock Price, News & Analysis $6.93 +0.02 (+0.29%) As of 11:45 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Emergent Biosolutions Stock (NYSE:EBS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Emergent Biosolutions alerts:Sign Up Key Stats Today's Range$6.81▼$7.0250-Day Range$4.44▼$7.5652-Week Range$4.36▼$14.06Volume199,700 shsAverage Volume967,466 shsMarket Capitalization$355.30 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingHold Company Overview Emergent BioSolutions Inc. (NYSE:EBS) is a life sciences company focused on developing, manufacturing and supplying medical countermeasures for public health threats, including chemical, biological, radiological and nuclear hazards, as well as infectious diseases. The company serves government agencies, healthcare providers and commercial customers. Emergent’s portfolio has included vaccines, therapeutics and other products used to prevent or treat serious health threats. Its offerings include BioThrax, an anthrax vaccine, and ACAM2000, a smallpox vaccine, along with products such as botulism antitoxin and vaccinia immune globulin. The company has also provided contract development and manufacturing services for pharmaceutical and biotechnology organizations. Founded in 1998, Emergent is headquartered in Gaithersburg, Maryland. Its operations and customer relationships have included the United States and international markets, with a significant portion of its business tied to government preparedness programs. Joseph C. Papa serves as the company’s chief executive officer.AI Generated. May Contain Errors. Read More Emergent Biosolutions Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks91st Percentile Overall ScoreEBS MarketRank™: 4.550910050115 of 5 starsEmergent Biosolutions scored higher than 91% of companies evaluated by MarketBeat, and ranked 93rd out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingHold Consensus RatingEmergent Biosolutions has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 2 sell ratings.Upside PotentialEmergent Biosolutions has a consensus price target of $10.00, representing about 44.0% upside from its current price of $6.95.Amount of Analyst CoverageEmergent Biosolutions has only been the subject of 4 research reports in the past 90 days.Read more about Emergent Biosolutions' stock forecast and price target. Earnings and Valuation3.8 / 5Proj. Earnings Growth469.23% Earnings GrowthEarnings for Emergent Biosolutions are expected to grow by 469.23% in the coming year, from $0.13 to $0.74 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Emergent Biosolutions is 4.85, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 35.91.Price to Earnings Ratio vs. SectorThe P/E ratio of Emergent Biosolutions is 4.85, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 204.95.Price to Book Value per Share RatioEmergent Biosolutions has a P/B Ratio of 0.70. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Emergent Biosolutions' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted19.28% of the float of Emergent Biosolutions has been sold short.Short Interest Ratio / Days to CoverEmergent Biosolutions has a short interest ratio ("days to cover") of 8.31.Change versus previous monthShort interest in Emergent Biosolutions has recently decreased by 5.03%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEmergent Biosolutions does not currently pay a dividend.Dividend GrowthEmergent Biosolutions does not have a long track record of dividend growth. News and Social Media2.3 / 5News Sentiment0.67 News SentimentEmergent Biosolutions has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Emergent Biosolutions this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for EBS on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Emergent Biosolutions insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $145,792.00 in company stock.Percentage Held by Insiders6.00% of the stock of Emergent Biosolutions is held by insiders.Percentage Held by Institutions78.40% of the stock of Emergent Biosolutions is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Emergent Biosolutions' insider trading history. Receive EBS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Emergent Biosolutions and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EBS Stock News HeadlinesComparing Sutro Biopharma (NASDAQ:STRO) & Emergent Biosolutions (NYSE:EBS)October 11 at 6:44 AM | americanbankingnews.comEmergent Biosolutions (NYSE:EBS) Director Donald Degolyer Sells 17,800 Shares of StockOctober 8, 2026 | insidertrades.comFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on page 84 is a plan that could expand oversight of checking accounts, purchases, and money transfers across the country. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what this document means and why it could roll out as soon as this summer.October 14 at 1:00 AM | Weiss Ratings (Ad)Emergent Biosolutions (NYSE:EBS) SVP Paul Anthony Williams Sells 3,000 Shares of Company StockOctober 6, 2026 | insidertrades.comInsider Selling: Emergent Biosolutions (NYSE:EBS) SVP Sells $19,590.00 in StockOctober 5, 2026 | americanbankingnews.comEmergent Biosolutions Inc. (NYSE:EBS) Stock Has Average Target Price of $10.00October 5, 2026 | americanbankingnews.comContrasting Immatics (NASDAQ:IMTX) and Emergent Biosolutions (NYSE:EBS)October 4, 2026 | americanbankingnews.comCaribou Biosciences (NASDAQ:CRBU) versus Emergent Biosolutions (NYSE:EBS) Head to Head ContrastOctober 3, 2026 | americanbankingnews.comSee More Headlines EBS Stock Analysis - Frequently Asked Questions How have EBS shares performed this year? Emergent Biosolutions' stock was trading at $12.35 at the beginning of the year. Since then, EBS shares have decreased by 43.8% and is now trading at $6.9450. How were Emergent Biosolutions' earnings last quarter? Emergent Biosolutions Inc. (NYSE:EBS) issued its quarterly earnings results on Wednesday, August, 5th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating analysts' consensus estimates of ($0.09) by $0.69. The biopharmaceutical company had revenue of $234.30 million for the quarter, compared to the consensus estimate of $177.50 million. Emergent Biosolutions had a negative net margin of 22.95% and a positive trailing twelve-month return on equity of 16.35%. Read the conference call transcript. Is Emergent Biosolutions doing a stock buyback? Emergent Biosolutions' board authorized a stock buyback plan on Monday, March 31st 2025, which allows the company to repurchase $50,000,000 in outstanding shares, according to EventVestor. This means that the company could purchase up to 19% of its shares through open market purchases. Shares buyback plans are usually an indication that the company's board of directors believes its stock is undervalued. How do I buy shares of Emergent Biosolutions? Shares of EBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Emergent Biosolutions own? Based on aggregate information from My MarketBeat watchlists, some other companies that Emergent Biosolutions investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Salesforce (CRM), PayPal (PYPL) and Netflix (NFLX). Company Calendar Last Earnings8/05/2026Today10/14/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 EBS's financial health is in the Yellow zone, according to TradeSmith. EBS has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSE:EBS CIK1367644 Webwww.emergentbiosolutions.com Phone(240) 631-3200Fax301-795-1899Employees900Year FoundedN/APrice Target and Rating Average Price Target for Emergent Biosolutions$10.00 High Price Target$10.00 Low Price Target$10.00 Potential Upside/Downside+44.5%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($3.55) Trailing P/E RatioN/A Forward P/E Ratio53.23 P/E GrowthN/ANet Income$52.60 million Net Margins-22.95% Pretax Margin-18.96% Return on Equity16.35% Return on Assets6.17% Debt Debt-to-Equity Ratio1.70 Current Ratio5.42 Quick Ratio2.95 Sales & Book Value Annual Sales$742.90 million Price / Sales0.48 Cash Flow$3.62 per share Price / Cash Flow1.91 Book Value$9.95 per share Price / Book0.70Miscellaneous Outstanding Shares51,270,000Free Float48,197,000Market Cap$354.79 million OptionableOptionable Beta2.28 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NYSE:EBS) was last updated on 10/14/2026 by MarketBeat.com Staff. From Our PartnersElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredTrump's about to unleash his Midterm WeaponTrump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...Monument Traders Alliance | SponsoredWall Street legend reveals his top AI stock before Oct. 20Marc Chaikin, the 60-year Wall Street veteran behind the Power Gauge rating system, has flagged a new AI stock...Chaikin Analytics | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredHow one AI fund pays investors every ThursdayOne small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling ...Investors Alley | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredFederal Reserve Reveals Disturbing New Plan To Control Your MoneyA Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's vis...Weiss Ratings | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Emergent Biosolutions Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Emergent Biosolutions With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EBS Stock Alerts